Neoplasm Proteins

Neoplasm Proteins
Accession Number

Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.

DrugDrug Description
BecaplerminA recombinant form of human platelet-derived growth factor used to treat ulcers due to diabetic neuropathy in the lower extremities when there is adequate blood supply to the area.
Nelipepimut-SInvestigated for use/treatment in prostate cancer and breast cancer.
Human papillomavirus type 16 L1 capsid protein antigenHuman papillomavirus type 16 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is...
TAK-448TAK-448 has been used in trials studying the treatment of Prostate Cancer, Low Testosterone, Prostatic Neoplasms, and Hypogonadotropic Hypogonadism.
IsoxaflutoleBalance has been investigated for the treatment of Chronic Renal Failure and Peritoneal Membrane Disorder.
Melanoma antigen recognized by T-cells 1Melanoma antigen recognized by T-cells 1 is under investigation in clinical trial NCT01748747 (Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery).
Kisspeptin-10Kisspeptin-10 is under investigation in clinical trial NCT03771326 (KP-10 and Insulin Secretion in Men).
GP-100 antigenGP-100 antigen is under investigation in clinical trial NCT00006385 (Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma).
Drugs & Drug Targets
BecaplerminPlatelet-derived growth factor receptor betatarget
BecaplerminPlatelet-derived growth factor receptor alphatarget
Nelipepimut-SHLA class I histocompatibility antigen, A-2 alpha chaintarget
Nelipepimut-SHLA class I histocompatibility antigen, A-3 alpha chaintarget